Botanix Pharmaceuticals (ASX:BOT) has today shared a market update and new data pertaining to the BTX 1801 antimicrobial program, which is currently being studied as part of a Phase 2a clinical trial in Perth.
The new data demonstrates BTX 1801 eliminates methicillin-resistant Staphylococcus aureus (‘MRSA’ or ‘Golden Staph’) from human skin explants infected with MRSA. It also confirms synthetic CBD’s novel mechanism of action, where treatment with CBD rapidly disrupts the bacteria’s membrane resulting in cell death.
The latest news was captured as part of a presentation shared by Botanix President and Executive Chairman, Vince Ippolito, for the ASX Small and Mid-Cap Conference today – which features a close-up look at the mechanism of action.
View the ASX Small & Mid-Cap Conference presentation:
The Botanix team is extremely encouraged by this new data and remains confident that BTX 1801 will be a valuable treatment option for the prevention of post-surgical infections, which are often serious and can be life-threatening. Addressing antimicrobial resistance (AMR) remains a foremost priority for the Company, alongside the largest health agencies in the world.